Skip to content
2000
image of Impaired Striatum Dopamine Release in Parkinson’s Disease

There is no abstract available.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673356301250130074521
2025-02-11
2025-09-07

  • From This Site

    /content/journals/cmc/10.2174/0109298673356301250130074521
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Olson M. Lockhart T.E. Lieberman A. Motor learning deficits in parkinson’s disease (PD) and their effect on training response in gait and balance: A narrative review. Front. Neurol. 2019 10 FEB 62 10.3389/fneur.2019.00062 30761061
    [Google Scholar]
  2. Doroszkiewicz J. Groblewska M. Mroczko B. Molecular biomarkers and their implications for the early diagnosis of selected neurodegenerative diseases. Int. J. Mol. Sci. 2022 23 9 4610 10.3390/ijms23094610 35563001
    [Google Scholar]
  3. Khatri D.K. Choudhary M. Sood A. Singh S.B. Anxiety: An ignored aspect of Parkinson’s disease lacking attention. Biomed. Pharmacother. 2020 131 110776 10.1016/j.biopha.2020.110776 33152935
    [Google Scholar]
  4. Prenger M.T.M. Madray R. Van Hedger K. Anello M. MacDonald P.A. Social symptoms of parkinson’s disease. Parkinsons Dis. 2020 2020 1 10 10.1155/2020/8846544 33489081
    [Google Scholar]
  5. Watanabe H. Dijkstra J.M. Nagatsu T. Parkinson’s Disease: Cells succumbing to lifelong dopamine-related oxidative stress and other bioenergetic challenges. Int. J. Mol. Sci. 2024 25 4 2009 10.3390/ijms25042009 38396687
    [Google Scholar]
  6. Gadhave D.G. Sugandhi V.V. Jha S.K. Nangare S.N. Gupta G. Singh S.K. Dua K. Cho H. Hansbro P.M. Paudel K.R. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res. Rev. 2024 99 102357 10.1016/j.arr.2024.102357 38830548
    [Google Scholar]
  7. Radlicka-Borysewska A. Jabłońska J. Lenarczyk M. Szumiec Ł. Harda Z. Bagińska M. Barut J. Pera J. Kreiner G. Wójcik D.K. Rodriguez Parkitna J. Non-motor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson’s disease. Front. Neurosci. 2024 18 April 1375265 10.3389/fnins.2024.1375265 38745938
    [Google Scholar]
  8. Masato A. Plotegher N. Boassa D. Bubacco L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol. Neurodegener. 2019 14 1 35 10.1186/s13024‑019‑0332‑6 30630532
    [Google Scholar]
  9. Bäckström D. Eriksson Domellöf M. Granåsen G. Linder J. Mayans S. Elgh E. Zetterberg H. Blennow K. Forsgren L. Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson’s disease. Acta Neurol. Scand. 2018 137 1 91 98 10.1111/ane.12812 28869277
    [Google Scholar]
  10. Salahuddin P. Fatima M.T. Uversky V.N. Khan R.H. Islam Z. Furkan M. The role of amyloids in Alzheimer’s and Parkinson’s diseases. Int. J. Biol. Macromol. 2021 190 44 55 10.1016/j.ijbiomac.2021.08.197 34480905
    [Google Scholar]
  11. Mehra S. Gadhe L. Bera R. Sawner A.S. Maji S.K. Structural and functional insights into α-synuclein fibril polymorphism. Biomolecules 2021 11 10 1419 10.3390/biom11101419 34680054
    [Google Scholar]
  12. Farotti L. Paolini Paoletti F. Simoni S. Parnetti L. Unraveling pathophysiological mechanisms of parkinson’s disease: Contribution of CSF biomarkers. Biomark. Insights 2020 15 10.1177/1177271920964077 33110345
    [Google Scholar]
  13. Mahboob A. Ali H. Alnaimi A. Yousef M. Al-muhannadi N. A. Kalana D. Senevirathne L. Rob M. Chaari A. Immunotherapy for parkinson’s disease and alzheimer’s disease: A promising disease-modifying therapy. Cells 2024 13 18 1527 10.3390/cells13181527
    [Google Scholar]
  14. van Oostveen W.M. de Lange E.C.M. Imaging Techniques in Alzheimer’s Disease: A review of applications in early diagnosis and longitudinal monitoring. Int. J. Mol. Sci. 2021 22 4 2110 10.3390/ijms22042110 33672696
    [Google Scholar]
  15. Dirkx M.F. Bologna M. The pathophysiology of Parkinson’s disease tremor. J. Neurol. Sci. 2022 435 120196 10.1016/j.jns.2022.120196 35240491
    [Google Scholar]
  16. Ramesh S. Arachchige A.S.P.M. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci. 2023 10 3 200 231 10.3934/Neuroscience.2023017 37841347
    [Google Scholar]
  17. Palmisano C. Brandt G. Vissani M. Pozzi N.G. Canessa A. Brumberg J. Marotta G. Volkmann J. Mazzoni A. Pezzoli G. Frigo C.A. Isaias I.U. Gait initiation in parkinson’s disease: impact of dopamine depletion and initial stance condition. Front. Bioeng. Biotechnol. 2020 8 March 137 10.3389/fbioe.2020.00137 32039188
    [Google Scholar]
  18. Ponsi G. Scattolin M. Villa R. Aglioti S.M. Human moral decision-making through the lens of Parkinson's disease. NPJ Park. Dis. 2021 7 1 18 10.1038/s41531‑021‑00167‑w 33654110
    [Google Scholar]
  19. Argerich J. Garma L.D. López-Cano M. Álvarez-Montoya P. Gómez-Acero L. Fernández-Dueñas V. Muñoz-Manchado A.B. Aso E. Boxer A. Andres-Benito P. GPR37 processing in neurodegeneration: A potential marker for Parkinson's Disease progression rate. NPJ Park. Dis. 2024 10 1 172 10.1038/s41531‑024‑00788‑x 39256360
    [Google Scholar]
  20. Meder D. Herz D.M. Rowe J.B. Lehéricy S. Siebner H.R. The role of dopamine in the brain - lessons learned from Parkinson’s disease. Neuroimage 2019 190 190 79 93 10.1016/j.neuroimage.2018.11.021 30465864
    [Google Scholar]
  21. Branigan K.S. Dotta B.T. Cognitive Decline: Current intervention strategies and integrative therapeutic approaches for alzheimer’s disease. Brain Sci. 2024 14 4 298 10.3390/brainsci14040298 38671950
    [Google Scholar]
  22. Meles S.K. Oertel W.H. Leenders K.L. Circuit imaging biomarkers in preclinical and prodromal Parkinson’s disease. Mol. Med. 2021 27 1 111 10.1186/s10020‑021‑00327‑x 34530732
    [Google Scholar]
  23. Waller S. Williams L. Morales-Briceño H. Fung V.S.C. The initial diagnosis and management of Parkinson’s disease. Aust. J. Gen. Pract. 2021 50 11 793 800 10.31128/AJGP‑07‑21‑6087 34713282
    [Google Scholar]
  24. Rizvi S.Z.H. Palimar V. Gupta C. Andrade L.S. Spectrum of non-motor symptoms in parkinson’s disease — a review. Anna. Clini. Exper. Neurol. 2024 18 3 72 80 10.17816/ACEN.1001
    [Google Scholar]
  25. Fabbri M. Coelho M. Garon M. Biundo R. Mestre T.A. Antonini A. Personalized care in late-stage parkinson’s disease: Challenges and opportunities. J. Pers. Med. 2022 12 5 813 10.3390/jpm12050813 35629235
    [Google Scholar]
  26. Willis A.W. Parkinson disease in the elderly adult. Mo Med. 2023 110 5 406 10 24279192
    [Google Scholar]
  27. Shin H.W. Hong S.W. Youn Y.C. Clinical aspects of the differential diagnosis of parkinson’s disease and parkinsonism. J. Clin. Neurol. 2022 18 3 259 270 10.3988/jcn.2022.18.3.259 35589315
    [Google Scholar]
  28. Koeglsperger T. Rumpf S.L. Schließer P. Struebing F.L. Brendel M. Levin J. Trenkwalder C. Höglinger G.U. Herms J. Neuropathology of incidental Lewy body & prodromal Parkinson’s disease. Mol. Neurodegener. 2023 18 1 32 10.1186/s13024‑023‑00622‑7 37173733
    [Google Scholar]
  29. Van Den Berge N. Ulusoy A. Animal models of brain-first and body-first Parkinson’s disease. Neurobiol. Dis. 2022 163 105599 10.1016/j.nbd.2021.105599 34952161
    [Google Scholar]
  30. Surmeier D.J. Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J. 2018 285 19 3657 3668 10.1111/febs.14607 30028088
    [Google Scholar]
  31. Formisano R. Rosikon K.D. Singh A. Dhillon H.S. The dopamine membrane transporter plays an active modulatory role in synaptic dopamine homeostasis. J. Neurosci. Res. 2022 100 8 1551 1559 10.1002/jnr.24965 34747520
    [Google Scholar]
  32. Egami K. Yitta S. Kasim S. Lewers J.C. Roberts R.C. Lehar M. Jinnah H.A. Basal ganglia dopamine loss due to defect in purine recycling. Neurobiol. Dis. 2007 26 2 396 407 10.1016/j.nbd.2007.01.010 17374562
    [Google Scholar]
  33. Salon J.A. Lodowski D.T. Palczewski K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol. Rev. 2011 63 4 901 937 10.1124/pr.110.003350 21969326
    [Google Scholar]
  34. Beaulieu J.M. Espinoza S. Gainetdinov R.R. Dopamine receptors – IUPHAR review 13. Br. J. Pharmacol. 2015 172 1 1 23 10.1111/bph.12906 25671228
    [Google Scholar]
  35. Asadi A. Madadi Asl M. Valizadeh A. Perc M. Dynamics of parkinsonian oscillations mediated by transmission delays in a mean-field model of the basal ganglia. Front. Cell. Neurosci. 2024 18 1344149 10.3389/fncel.2024.1344149 38550919
    [Google Scholar]
  36. Chantranupong L. Beron C.C. Zimmer J.A. Wen M.J. Wang W. Sabatini B.L. Dopamine and glutamate regulate striatal acetylcholine in decision-making. Nature 2023 621 7979 577 585 10.1038/s41586‑023‑06492‑9 37557915
    [Google Scholar]
  37. Cramb K.M.L. Beccano-Kelly D. Cragg S.J. Wade-Martins R. Impaired dopamine release in Parkinson’s disease. Brain 2023 146 8 3117 3132 10.1093/brain/awad064 36864664
    [Google Scholar]
  38. Kawahata I. Finkelstein D.I. Fukunaga K. Dopamine D1–D5 Receptors in Brain Nuclei: Implications for health and disease. Receptors 2024 3 2 155 181 10.3390/receptors3020009
    [Google Scholar]
  39. Neupane S. De Cecco E. Aguzzi A. The hidden cell-to-cell trail of α-synuclein aggregates. J. Mol. Biol. 2023 435 12 167930 10.1016/j.jmb.2022.167930 36566800
    [Google Scholar]
  40. Shen W. Zhai S. Surmeier D.J. Striatal synaptic adaptations in Parkinson’s disease. Neurobiol. Dis. 2022 167 105686 10.1016/j.nbd.2022.105686 35272023
    [Google Scholar]
  41. Halli-tierney A.D. Luker J. A comprehensive approach to parkinson’s disease: Addressing its molecular, clinical, and therapeutic aspects. Park. Dis. 2020 102 11 172838
    [Google Scholar]
  42. Özçete Ö.D. Banerjee A. Kaeser P.S. Mechanisms of neuromodulatory volume transmission. Mol. Psychiatry 2024 29 11 3680 3693 10.1038/s41380‑024‑02608‑3 38789677
    [Google Scholar]
  43. Freed W.J. Motive Desire A New W. to Think About Why We Do Everything Its Basis Neuroscience. Cham Springer International Publishing 2022 10.1007/978‑3‑031‑10477‑0
    [Google Scholar]
  44. Hauser R.A. LeWitt P.A. Comella C.L. Hauser R.A. Lewitt P.A. Comella C.L. On demand therapy for Parkinson’s disease patients: Opportunities and choices. Postgrad. Med. 2021 133 7 721 727 10.1080/00325481.2021.1936087 34082655
    [Google Scholar]
  45. Haddad F. Sawalha M. Khawaja Y. Najjar A. Karaman R. Dopamine and levodopa prodrugs for the treatment of parkinson’s disease. Molecules 2017 23 1 40 10.3390/molecules23010040 29295587
    [Google Scholar]
  46. Carroll V. Rossiter R. Blanchard D. Non-motor symptoms of Parkinson’s disease. Aust. J. Gen. Pract. 2021 50 11 812 817 10.31128/AJGP‑07‑21‑6093 34713279
    [Google Scholar]
  47. Dong-Chen X. Yong C. Yang X. Chen-Yu S. Li-Hua P. Signaling pathways in Parkinson’s disease: Molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 2023 8 1 73 10.1038/s41392‑023‑01353‑3 36810524
    [Google Scholar]
  48. Yamashita K.Y. Bhoopatiraju S. Silverglate B.D. Grossberg G.T. Biomarkers in Parkinson’s disease: A state of the art review. Biomark. Neuropsychia. 2023 9 100074 10.1016/j.bionps.2023.100074
    [Google Scholar]
  49. Jost S.T. Kaldenbach M.A. Antonini A. Martinez-Martin P. Timmermann L. Odin P. Katzenschlager R. Borgohain R. Fasano A. Stocchi F. Hattori N. Kukkle P.L. Rodríguez-Violante M. Falup-Pecurariu C. Schade S. Petry-Schmelzer J.N. Metta V. Weintraub D. Deuschl G. Espay A.J. Tan E.K. Bhidayasiri R. Fung V.S.C. Cardoso F. Trenkwalder C. Jenner P. Ray Chaudhuri K. Dafsari H.S. Levodopa Dose Equivalency in Parkinson’s Disease: Updated systematic review and proposals. Mov. Disord. 2023 38 7 1236 1252 10.1002/mds.29410 37147135
    [Google Scholar]
  50. Adam H. Gopinath S. C. B. Md Arshad M. K. Adam T. Parmin N. A. Husein I. Hashim U. An update on pathogenesis and clinical scenario for Parkinson's disease: Diagnosis and treatment 3 Biotech 2023 13 5 142 10.1007/s13205‑023‑03553‑8
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673356301250130074521
Loading
Impaired Striatum Dopamine Release in Parkinson’s Disease
Bentham Science Publishers ; https://doi.org/10.2174/0109298673356301250130074521
/content/journals/cmc/10.2174/0109298673356301250130074521
/content/journals/cmc/10.2174/0109298673356301250130074521
Loading

Data & Media loading...


  • Article Type:     Editorial

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test